glp 1 hair loss Weight and Loss Hair loss from GLP-1 Injections
Description
This tool helps identify duplicate GLP-1 therapy and inappropriate use through three targeted models: GLP-1 Concurrent Use : Flags members using multiple GLP-1 medications within a defined timeframe

The CVOT of oral semaglutide in people with type 2 diabetes and established CVD, chronic kidney disease (CKD) or both demonstrated a significant reduction in MACE compared with placebo (McGuire et al, 2025)

Challenges, Side Effects, and Cost Gastrointestinal symptoms like nausea and diarrhea are common with GLP1 therapies, including oral versions

The time it took these patients to develop PDR was 325 days in the GLP-1 receptor agonist group and 232 days in the control group
